依达拉奉配合普罗布考治疗缺血性脑卒中的效果及对患者近期预后的影响

Effect of Edaravone Combined with Probucol in the Treatment of Ischemic Stroke and the Impact on Short-Term Prognosis

目的探讨依达拉奉配合普罗布考治疗缺血性脑卒中(IS)的效果及对患者近期预后的影响。方法将2022年11月至2023年10月我院收治的110例IS患者,按照入组顺序分为两组。对照组采用依达拉奉治疗,观察组采用依达拉奉配合普罗布考治疗。比较两组治疗效果、血清指标及预后。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,观察组SOD高于对照组,NSE、hs-CRP低于对照组(P<0.05)。观察组短期预后良好率高于对照组(P<0.05)。结论依达拉奉联合普罗布考治疗IS的效果较好,可改善患者的短期预后,其机制可能与调节SOD、NSE、hs-CRP的表达有关。

Objective To analyze the effect of edaravone combined with probuco in the treatment of ischemic stroke(IS)and the impact on the short-term prognosis.Methods 110 IS patients admitted to our hospital from November 2022 to October 2023 were selected and divided into two groups according to the enrollment order.The control group was treated with edaravone,and the observation group was treated with edaravone combined with probucol.The treatment effect,serum indicators and prognosis of the two groups were compared.Results The total effective rate of observation group was higher than that of control group(P<0.05).After treatment,the SOD of the observation group was higher than that of the control group,and the NSE and hs-CRP were lower than those of the control group(P<0.05).The good short-term prognosis rate of the observation group was higher than that of the control group(P<0.05).Conclusions Edaravone combined with probucol has better treatment effect on IS,and can improve the short-term prognosis of patients,which mechanism may be related to regulating the expressions of SOD,NSE and hs-CRP.